• 

  Genetic and environmental risk factors for rheumatoid arthritis in a UK African ancestry population: the GENRA case-control study 

  Traylor, M; Curtis, C; Patel, H; Breen, G; Hyuck Lee, S; Xu, X; Newhouse, SDobson, RSteer, SCope, APMarkus, HSLewis, CMScott, IC et al.

  $\textbf{Objectives}$.: To evaluate whether genetic and environmental factors associated with RA in European and Asian ancestry populations are also associated with RA in African ancestry individuals. $\textbf{Methods}$.: ...
• 

  Succinate supplementation improves metabolic performance of mixed glial cell cultures with mitochondrial dysfunction 

  Giorgi-Coll, S; Amaral, AI; Hutchinson, PJA; Kotter, MR; Carpenter, KLH (Nature Publishing Group, 2017-04-21)

  Mitochondrial dysfunction, the inability to efficiently utilise metabolic fuels and oxygen, contributes to pathological changes following traumatic spinal cord or traumatic brain injury (TBI). In the present study, we ...
• 

  Heparin-gold nanoparticles for enhanced microdialysis sampling 

  Giorgi-Coll, S; Blunt-Foley, H; Carpenter, KLH; Hutchinson, PJAH

  Cerebral microdialysis is a sampling technique which offers much potential for understanding inflammatory pathophysiology following traumatic brain injury (TBI). At present, the recovery of cytokines via microdialysis in ...
• 

  Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy 

  Havrdova, E; Arnold, DL; Cohen, JA; Hartung, HP; Fox, EJ; Giovannoni, G; Schippling, SSelmaj, KWTraboulsee, ACompston, DASMargolin, DHThangavelu, KPanzara, MAColes, AJon behalf of CARE-MS I and CAMMS03409 Investigators et al.

  $\textbf{Objective}$: Evaluate 5-year efficacy and safety of alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis (RRMS). $\textbf{Methods}$: Alemtuzumab-treated patients in CARE-MS ...

View more